Regulating Bioprospecting: Institutions for Drug Research, Access, and Benefit Sharing

“A welcome contribution to an important but highly polarized debate. It offers an objective and academically rigorous treatment of what is a highly complex subject, and in doing so should contribute to fairer and more effective bioprospecting regulation.” –Graham Dutfield, Queen Mary Intellectual Property Research Institute, University of London, UK

“An excellent and comprehensive overview of the many complex facets of the bioprospecting and drug discovery and development process, and an invaluable source of information and guidance to those seeking to establish programs and agreements built on foundations of reasonable access and equitable benefit-sharing.” –Gordon Cragg, Former Director, Natural Products Branch, National Cancer Institute, USA

“The author examines, with outstanding analytical capabilities, complex economic issues of particular importance to developing countries and the drug industry. The book offers stimulating insights in a rigorous and accessible manner. It will be of great value for researchers, policy makers, managers, and all those concerned with the protection and sustainable use of biodiversity.” –Carlos M. Correa, University of Buenos Aires, Argentina

“This book is a significant contribution to the literature and will stimulate valuable discourse.” –Daniel B. Magraw, “Centre for International Environmental Law, Washington, USA”

“Dr Gehl Sampath’s book is a welcome contribution to an important but highly polarized debate. It offers an objective and academically rigorous treatment of what is a highly complex subject, and in doing so should contribute to fairer and more effective bioprospecting regulation.”

Padmashree Gehl Sampath is a researcher at the United Nations University Institute for New Technologies (UNU-INTECH). She has consulted for the WHO Commission on Intellectual Property, Innovation and Health, UNCTAD, the European Commission, and the German Government.